|
|
||||||||
1 Departments of Anesthesiology and Pharmacology, and 2 Endocrinology and Metabolism, Mayo Clinic, Rochester, Minnesota 55905
Our previous ex vivo
and in vivo studies reported that expression of the recombinant
endothelial nitric oxide (NO) synthase (eNOS) gene in adventitial
fibroblasts recovers NO production in arteries without endothelium in
response to bradykinin. The present study was designed to characterize
subtypes of bradykinin receptors on adventitial fibroblasts coupled to
the activation of recombinant eNOS. Endothelium-denuded segments of
canine basilar arteries were transduced with
-galactosidase
(
-Gal) gene or eNOS gene ex vivo, using a replication-defective
adenoviral vector (1010 plaque-forming units/ml) for 30 min
at 37°C. Twenty-four hours later, isometric force recording or cGMP
measurement was carried out. B1 bradykinin receptor agonist
(des-Arg9-bradykinin,
10
10-10
8
mol/l) did not significantly affect vascular tone in control or
-Gal
gene-transduced canine basilar arteries without endothelium. In
contrast, this agonist caused concentration-dependent relaxations in
recombinant eNOS gene-transduced arteries without endothelium. Relaxations to B1 receptor agonist in the eNOS arteries
were abolished by B1 receptor antagonist
(des-Arg9-[Leu8]bradykinin, 6 × 10
9 mol/l) but not by
B2 receptor antagonist (Hoe-140, 5 × 10
8 mol/l). Bradykinin did not
significantly alter vascular tone in control or
-gal arteries
without endothelium, whereas this peptide
(10
11-10
8
mol/l) induced concentration-dependent relaxations, as well as an
increase in cGMP formation in endothelium-denuded eNOS-transduced arteries. Stimulatory effects of bradykinin were prevented in the
presence of a B2 receptor antagonist but not in the
presence of a B1 receptor antagonist. B1 and
B2 receptor antagonists had no effect on relaxations to
substance P, confirming the selectivity of the compounds. Our results
suggest that B1 and B2 bradykinin receptors are
coupled to activation of recombinant eNOS expressed in adventitial fibroblasts.
des-Arg9-[Leu8]bradykinin; Hoe-140; gene transfer
This article has been cited by other articles:
![]() |
L. M. F. Leeb-Lundberg, F. Marceau, W. Muller-Esterl, D. J. Pettibone, and B. L. Zuraw International Union of Pharmacology. XLV. Classification of the Kinin Receptor Family: from Molecular Mechanisms to Pathophysiological Consequences Pharmacol. Rev., March 1, 2005; 57(1): 27 - 77. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Aschner, T. K. Smith, N. Kovacs, J. M. B. Pinheiro, and M. Fuloria Mechanisms of bradykinin-mediated dilation in newborn piglet pulmonary conducting and resistance vessels Am J Physiol Lung Cell Mol Physiol, August 1, 2002; 283(2): L373 - L382. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Lacza, M. Puskar, B. Kis, J. V. Perciaccante, A. W. Miller, and D. W. Busija Hydrogen peroxide acts as an EDHF in the piglet pial vasculature in response to bradykinin Am J Physiol Heart Circ Physiol, July 1, 2002; 283(1): H406 - H411. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. G. Khurana, L. A. Smith, T. A. Baker, D. Eguchi, T. O'Brien, and Z. S. Katusic Protective Vasomotor Effects of In Vivo Recombinant Endothelial Nitric Oxide Synthase Gene Expression in a Canine Model of Cerebral Vasospasm Stroke, March 1, 2002; 33(3): 782 - 789. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |